FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560624069> ?p ?o ?g. }

• W2560624069 endingPage "e1002162" @default.
• W2560624069 startingPage "e1002162" @default.
• W2560624069 abstract "Background Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and has a high risk of distant metastasis at every disease stage. We aimed to characterize the genomic landscape of LUAD and identify mutation signatures associated with tumor progression. Methods and Findings We performed an integrative genomic analysis, incorporating whole exome sequencing (WES), determination of DNA copy number and DNA methylation, and transcriptome sequencing for 101 LUAD samples from the Environment And Genetics in Lung cancer Etiology (EAGLE) study. We detected driver genes by testing whether the nonsynonymous mutation rate was significantly higher than the background mutation rate and replicated our findings in public datasets with 724 samples. We performed subclonality analysis for mutations based on mutant allele data and copy number alteration data. We also tested the association between mutation signatures and clinical outcomes, including distant metastasis, survival, and tumor grade. We identified and replicated two novel candidate driver genes, POU class 4 homeobox 2 (POU4F2) (mutated in 9 [8.9%] samples) and ZKSCAN1 (mutated in 6 [5.9%] samples), and characterized their major deleterious mutations. ZKSCAN1 was part of a mutually exclusive gene set that included the RTK/RAS/RAF pathway genes BRAF, EGFR, KRAS, MET, and NF1, indicating an important driver role for this gene. Moreover, we observed strong associations between methylation in specific genomic regions and somatic mutation patterns. In the tumor evolution analysis, four driver genes had a significantly lower fraction of subclonal mutations (FSM), including TP53 (p = 0.007), KEAP1 (p = 0.012), STK11 (p = 0.0076), and EGFR (p = 0.0078), suggesting a tumor initiation role for these genes. Subclonal mutations were significantly enriched in APOBEC-related signatures (p < 2.5×10−50). The total number of somatic mutations (p = 0.0039) and the fraction of transitions (p = 5.5×10−4) were associated with increased risk of distant metastasis. Our study’s limitations include a small number of LUAD patients for subgroup analyses and a single-sample design for investigation of subclonality. Conclusions These data provide a genomic characterization of LUAD pathogenesis and progression. The distinct clonal and subclonal mutation signatures suggest possible diverse carcinogenesis pathways for endogenous and exogenous exposures, and may serve as a foundation for more effective treatments for this lethal disease. LUAD’s high heterogeneity emphasizes the need to further study this tumor type and to associate genomic findings with clinical outcomes." @default.
• W2560624069 created "2016-12-16" @default.
• W2560624069 creator A5001980972 @default.
• W2560624069 creator A5008106632 @default.
• W2560624069 creator A5013336052 @default.
• W2560624069 creator A5013635303 @default.
• W2560624069 creator A5016557698 @default.
• W2560624069 creator A5019329822 @default.
• W2560624069 creator A5020329452 @default.
• W2560624069 creator A5022867480 @default.
• W2560624069 creator A5023709836 @default.
• W2560624069 creator A5023950836 @default.
• W2560624069 creator A5024230741 @default.
• W2560624069 creator A5025520229 @default.
• W2560624069 creator A5026919585 @default.
• W2560624069 creator A5034936483 @default.
• W2560624069 creator A5037068227 @default.
• W2560624069 creator A5039857143 @default.
• W2560624069 creator A5048679350 @default.
• W2560624069 creator A5051368343 @default.
• W2560624069 creator A5052027280 @default.
• W2560624069 creator A5053530719 @default.
• W2560624069 creator A5053781606 @default.
• W2560624069 creator A5056579154 @default.
• W2560624069 creator A5058535702 @default.
• W2560624069 creator A5067361490 @default.
• W2560624069 creator A5067533895 @default.
• W2560624069 creator A5071811696 @default.
• W2560624069 creator A5076801304 @default.
• W2560624069 creator A5076808228 @default.
• W2560624069 creator A5077852553 @default.
• W2560624069 creator A5082768586 @default.
• W2560624069 creator A5083213632 @default.
• W2560624069 creator A5083215290 @default.
• W2560624069 creator A5087166167 @default.
• W2560624069 creator A5091653870 @default.
• W2560624069 date "2016-12-06" @default.
• W2560624069 modified "2023-10-16" @default.
• W2560624069 title "Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study" @default.
• W2560624069 cites W1571666545 @default.
• W2560624069 cites W1659768997 @default.
• W2560624069 cites W1903281529 @default.
• W2560624069 cites W1965646154 @default.
• W2560624069 cites W1968065996 @default.
• W2560624069 cites W1973910854 @default.
• W2560624069 cites W1973979318 @default.
• W2560624069 cites W1974740818 @default.
• W2560624069 cites W1978236936 @default.
• W2560624069 cites W1981083257 @default.
• W2560624069 cites W1981989535 @default.
• W2560624069 cites W1990057158 @default.
• W2560624069 cites W1992246715 @default.
• W2560624069 cites W1997495854 @default.
• W2560624069 cites W2003316240 @default.
• W2560624069 cites W2003665515 @default.
• W2560624069 cites W2009720434 @default.
• W2560624069 cites W2021073156 @default.
• W2560624069 cites W2029623390 @default.
• W2560624069 cites W2035228518 @default.
• W2560624069 cites W2037210963 @default.
• W2560624069 cites W2038268416 @default.
• W2560624069 cites W2042386784 @default.
• W2560624069 cites W2054903577 @default.
• W2560624069 cites W2055402151 @default.
• W2560624069 cites W2065799563 @default.
• W2560624069 cites W2071392860 @default.
• W2560624069 cites W2088580309 @default.
• W2560624069 cites W2089039717 @default.
• W2560624069 cites W2094251872 @default.
• W2560624069 cites W2097238709 @default.
• W2560624069 cites W2104224322 @default.
• W2560624069 cites W2108371618 @default.
• W2560624069 cites W2114031931 @default.
• W2560624069 cites W2122133689 @default.
• W2560624069 cites W2122769974 @default.
• W2560624069 cites W2124988709 @default.
• W2560624069 cites W2131279093 @default.
• W2560624069 cites W2131876608 @default.
• W2560624069 cites W2138100316 @default.
• W2560624069 cites W2138601221 @default.
• W2560624069 cites W2141811925 @default.
• W2560624069 cites W2152061559 @default.
• W2560624069 cites W2154974159 @default.
• W2560624069 cites W2157852151 @default.
• W2560624069 cites W2162471699 @default.
• W2560624069 cites W2163798887 @default.
• W2560624069 cites W2180481128 @default.
• W2560624069 cites W2262414037 @default.
• W2560624069 cites W2287386959 @default.
• W2560624069 cites W2329888282 @default.
• W2560624069 cites W4230962320 @default.
• W2560624069 doi "https://doi.org/10.1371/journal.pmed.1002162" @default.
• W2560624069 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5140047" @default.
• W2560624069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27923066" @default.
• W2560624069 hasPublicationYear "2016" @default.
• W2560624069 type Work @default.
• W2560624069 sameAs 2560624069 @default.
• W2560624069 citedByCount "128" @default.

• next